SynthesisDiabetologia2003
Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies.
Synthesis in Diabetologia, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Relationship between melatonin receptor 1B and insulin receptor substrate 1 polymorphisms with gestational diabetes mellitus: a systematic review and meta-analysis.Scientific reports · 2014Pooled it
- Genetic prediction of future type 2 diabetes.PLoS medicine · 2005Trial
- Role and mechanism ofFrontiers in pharmacology · 2024Article
- Mendelian randomization study of diabetes and dementia in the Million Veteran Program.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Mendelian randomization study of diabetes and dementia in the Million Veteran Program.medRxiv : the preprint server for health sciences · 2023Article
- Polycystic Ovarian Syndrome: A Complex Disease with a Genetics Approach.Biomedicines · 2022Review
- A Missense Mutation in IRS1 is Associated with the Development of Early-Onset Type 2 Diabetes.International journal of endocrinology · 2020Article
- The combined role of allelic variants ofDiabetology & metabolic syndrome · 2019Article
- Non-alcoholic fatty liver disease: a narrative review of genetics.Journal of biomedical research · 2018Article
- Genetic variation in TNFα, PPARγ, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort.Breast cancer research and treatment · 2018Article
- Gly972Arg of IRS-1 and Lys121Gln of PC-1 polymorphisms act in opposite way in polycystic ovary syndrome.Journal of endocrinological investigation · 2017Article
- MAP4K4 and IL-6Journal of biomedical science · 2017Review
- IRS proteins and diabetic complications.Diabetologia · 2016Review
- Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.The pharmacogenomics journal · 2016Review
- Susceptibility of Different Mouse Wild Type Strains to Develop Diet-Induced NAFLD/AFLD-Associated Liver Disease.PloS one · 2016Article
- Genetic background in nonalcoholic fatty liver disease: A comprehensive review.World journal of gastroenterology · 2015Review
- mTOR in health and in sickness.Journal of molecular medicine (Berlin, Germany) · 2015Review
- Article
- Association of the genetic variants of insulin receptor substrate 1 (IRS-1) with type 2 diabetes mellitus in a Saudi population.Endocrine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisSeveral case-control studies have examined the association between the Gly972Arg variant in the IRS-1 gene and Type 2 diabetes, but most had limited power and results could therefore be conflicting.
methodsWe systematically reviewed the literature by means of a meta-analysis and investigated sources of heterogeneity in results of different studies.
resultsThe summary risk ratio, based on 3408 cases and 5419 control cases from 27 studies, was 1.25 (95% CI 1.05-1.48). The results, however, differed according to the type of study, method of verifying non-diabetic status of the control subjects, and age of the case subjects. Population-based studies reported lower odds ratios than hospital-based studies (OR 0.98, 95% CI 0.74-1.30 vs OR 1.43, 95% CI 1.17-1.74). Also, the diagnostic test to exclude diabetes amongst control subjects interacted with the association between the IRS-1 Gly972Arg variant and Type 2 diabetes (p=0.03). Finally, the odds ratio reduced with increasing age ( p=0.03). CONCLUSION/
interpretationOverall, carriers of the 972Arg variant of the IRS-1 gene are at a 25% increased risk of having Type 2 diabetes compared with non-carriers. The odds ratios are generally higher in hospital-based studies, including relatively young, symptomatic, cases.
Indexed as
Identifiers
12819898What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.